Osaka, Japan-based drugmaker Shionogi has filed for conditional approval in Japan. (Wikimedia Commons) Shionogi is about to find out what it takes to get a COVID-19 antiviral to market in Japan.
Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels tested Plans to pursue rapid initiation of ...
Positive phase III top-line results for Valneva SA’s chikungunya virus vaccine candidate, VLA-1553, show the study met its primary endpoint of inducing neutralizing antibody titers, setting it up for ...
One of the most often used and least understood immunological terms is antibody titer. But what does titer mean, and how can this information be used in assessing the immune status of a horse? A titer ...
An antibody titer test identifies and measures the amount of antibodies in your blood, which indicates the strength of your immune response. Doctors use this test to determine if you’ve had past ...
Phase 3 success: The ADAPT OCULUS trial in ocular MG met its primary endpoint (VYVGART high‑titer vs placebo, p=0.012), was well tolerated, and argenx plans to present broader data and file a ...
Positive phase III top-line results for Valneva SA’s chikungunya virus vaccine candidate, VLA-1553, show the study met its primary endpoint of inducing neutralizing antibody titers, setting it up for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results